| For: | Wang Z, Zhang RY, Xu YF, Yue BT, Zhang JY, Wang F. Unmasking immune checkpoint resistance in esophageal squamous cell carcinoma: Insights into the tumor microenvironment and biomarker landscape. World J Gastrointest Oncol 2025; 17(8): 109489 [PMID: 40837744 DOI: 10.4251/wjgo.v17.i8.109489] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5204/full/v17/i8/109489.htm |
| Number | Citing Articles |
| 1 |
Zhenglin He, Hanming Hao, Xinyang Shu, Yifei Ren, Yishuo Ji, Kai Zhao, Yimeng Chen, Liang Han, Yue Hu. Immunosuppressive tumor microenvironment and immunotherapy resistance of esophageal carcinoma. Frontiers in Immunology 2026; 17 doi: 10.3389/fimmu.2026.1926551
|
| 2 |
Dapeng Wu, Wei Chen, Qi Zhao, Wenjing Zhu, Jian Xu. Antibody-Drug Conjugates in the Treatment of Esophageal Cancer. Current Treatment Options in Oncology 2026; 27(1) doi: 10.1007/s11864-026-01411-2
|
| 3 |
Haoyue Lai, Lu Qi, Zhixuan Lin, Zhongwen Li. The multidimensional regulatory network of the PD‑1/PD‑L1 axis in the esophageal squamous cell carcinoma microenvironment: Implications for novel combination therapies and precision immunotherapy (Review). Oncology Reports 2025; 55(1) doi: 10.3892/or.2025.9021
|
| 4 |
Zhifeng Qu, Xuewei Zheng, Anshun Zhao, Pei Wang, Shegan Gao, Qinan Yin. Mast cell driven immunometabolism as a therapeutic entry point in ESCC. Frontiers in Cell and Developmental Biology 2026; 14 doi: 10.3389/fcell.2026.1830394
|
| 5 |
Shigeto Nakai, Tomoki Makino, Kota Momose, Kotaro Yamashita, Koji Tanaka, Hiroshi Miyata, Sachiko Yamamoto, Masaaki Motoori, Yutaka Kimura, Tomohira Takeoka, Motohiro Hirao, Jin Matsuyama, Yusuke Akamaru, Yukinori Kurokawa, Eiichi Morii, Hidetoshi Eguchi, Yuichiro Doki. NY-ESO-1 and PD-L1 as biomarkers associated with nivolumab response and outcome in unresectable or recurrent esophageal squamous cell carcinoma: a multicenter biomarker study. Cancer Immunology, Immunotherapy 2026; 75(7) doi: 10.1007/s00262-026-04415-x
|
| 6 |
Yingjian Wang, Zhe Wang, Fangdi Zhou, Yu Qiao, Zhanyang Luo, Feng Wang, Bingtong Yue, Dao Xin. Cancer-associated fibroblasts as architects of acquired immune-privileged-like niches in gastrointestinal cancers: lessons from ocular immune privilege and barrier biology. Frontiers in Immunology 2026; 17 doi: 10.3389/fimmu.2026.1946857
|
| 7 |
Xuejun Guo, Shuhan Ma, Jingwen Wang, Yilin Fu, Wenxue Ma. Terminally exhausted CD8+ T cells in solid tumors: biology, biomarker potential and translational tools for precision oncology. Frontiers in Immunology 2026; 16 doi: 10.3389/fimmu.2025.1709852
|
| 8 |
Yi Xu, Xianhao Wang, Yujiao Sun, Xinyi Ye, Yingyin Gao, Luxi Li, Yue Wu, Keyi Zhou, Yunzhi Pan, Sai Ma. Establishment and multi-omics characterization of a PD-1-resistant murine esophageal squamous cell carcinoma cell line. Biochemical and Biophysical Research Communications 2026; 828 doi: 10.1016/j.bbrc.2026.154109
|